Back

Antiplatelet pretreatment in NSTE-ACS: do we have the answer?

18 March 2022 (12:38 - 12:51)
Organised by:
Congress Presentation Part of: Anti-thrombotic management in patients with acute coronary syndromes (ACS) Thrombosis, Platelets, and Coagulation ACVC Premium Access ESC Acute CardioVascular Care 2022

About the speaker

Photo
Doctor Piera Capranzano

University of Catania, Catania (Italy)

4 More presentations in this session

Presentation thumbnail
The novel subcutaneously administered glycoprotein IIb/IIIa antagonist RUC-4 (Zalunfiban) did not cause thrombocytopenia in the phase 2a study of patients with ST-elevation myocardial infarction
Mr S. Rikken (Nieuwegein, NL)
Abstract Slides Video
Presentation thumbnail
Do we really need aspirin?
Professor R. Mehran (New York City, US)
Slides Video
Presentation thumbnail
Extended, standard or de-escalation antiplatelet therapy after ACS?
Professor K. Huber (Vienna, AT)
Slides Video
Presentation thumbnail
Anti-thrombotic management in patients with acute coronary syndromes - discussion.
Video

Access the full session

Session thumbnail
Anti-thrombotic management in patients with acute coronary syndromes (ACS)
Video

The Event

Event poster

ESC Acute CardioVascular Care 2022

18 March 2022 12:38 CET
You may be interested in
thumbnail
Congress Presentation
Impact of pretreatment with P2Y12 receptor inhibitors on type 4a myocardial infarction and bleeding in patients with non-ST-segment elevation myocardial infarction: a propensity score matching study
thumbnail
Congress Session
Antiplatelet therapy: novel approaches for acute coronary syndrome and percutaneous coronary intervention
thumbnail
Congress Session
Oral antiplatelet therapy after acute coronary syndromes: how to choose the best regimen and the optimum duration

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources